
Scientists at UW Medicine and the NIH have created an experimental flu vaccine that spurs broad immunity in animal trials
Researchers have developed experimental flu shots that protect animals from a wide variety of seasonal and pandemic influenza strains. The vaccine product is currently being advanced toward clinical testing. If proven safe and effective, these next-generation influenza vaccines may replace current seasonal options by providing protection against many more strains that current vaccines do not adequately cover.
A study detailing how the new flu vaccines were designed and how they protect mice, ferrets, and nonhuman primates appears in the March 24 edition of the journal Nature. This work was led by researchers at the University of Washington School of Medicine and the Vaccine Research Center part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Influenza virus causes an estimated 290,000–650,000 deaths per year. Available flu vaccines, which need to be taken seasonally, often fail to protect against many circulating flu strains that cause illness, and the threat of another influenza pandemic looms.
“Most flu shots available today are quadrivalent, meaning they are made from four different flu strains. Each year, the World Health Organization makes a bet on which four strains will be most prevalent, but those predictions can be more or less accurate. This is why we often end up with ‘mismatched’ flu shots that are still helpful but only partially effective,” said lead author Daniel Ellis, a research scientist in the laboratory of Neil King. King is an assistant professor of biochemistry at the UW School of Medicine and a researcher at the Institute for Protein Design at UW Medicine.
To create improved influenza vaccines, the team attached hemagglutinin proteins from four different influenza viruses to custom-made protein nanoparticles. This approach enabled an unprecedented level of control over the molecular configuration of the resulting vaccine and yielded an improved immune response compared to conventional flu shots. The new nanoparticle vaccines, which contain the same four hemagglutinin proteins of commercially available quadrivalent influenza vaccines, elicited neutralizing antibody responses to vaccine-matched strains that were equivalent or superior to the commercial vaccines in mice, ferrets, and nonhuman primates. The nanoparticle vaccines—but not the commercial vaccines —also induced protective antibody responses to viruses not contained in the vaccine formulation. These include avian influenza viruses H5N1 and H7N9, which are considered pandemic threats.
The responses that our vaccine gives against strain-matched viruses are really strong, and the additional coverage we saw against mismatched strains could lower the risk of a bad flu season,” said Ellis.
Original Article: Nanoparticle flu shot blocks seasonal and pandemic strains
More from: University of Washington School of Medicine | National Institutes of Health
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Experimental flu vaccine
- A Life-Extension Drug for Big Dogs Is Getting Closer to Reality
The FDA has yet to approve any drugs for life extension. But biotech company Loyal is now a step closer to bringing one to market—for dogs.
- Decades of mRNA Research Come to Fruition
Thermo Fisher Scientific argues that mRNA-based COVID-19 vaccines merely hint at the mRNA-based applications that are already in the works.
- Covid’s true origin must be investigated
The emergence of a mystery respiratory illness affecting children in northern China has echoes of the start of the Covid pandemic in 2020. Hospitals in the region are reportedly overcrowded with sick ...
- Influenza News
Nov. 13, 2023 — Despite national medical guidelines supporting the use of antiviral medications in young children diagnosed with influenza, a new study reports an ...
- Influenza is here. What can Albertans expect?
Influenza has arrived in Alberta and while its gaining traction later in the season than last year, some are concerned that with COVID-19 hospitalizations remaining high, hospitals could struggle ...
Go deeper with Google Headlines on:
Experimental flu vaccine
[google_news title=”” keyword=”experimental flu vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Nanoparticle flu vaccine
- Decades of mRNA Research Come to Fruition
Thermo Fisher Scientific argues that mRNA-based COVID-19 vaccines merely hint at the mRNA-based applications that are already in the works.
- Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine
2 We recently described an adjuvanted recombinant hemagglutinin (HA) trivalent nanoparticle influenza vaccine (tNIV), produced on an Sf9 insect cell–recombinant baculovirus platform made from ...
- Influenza News
Nov. 13, 2023 — Despite national medical guidelines supporting the use of antiviral medications in young children diagnosed with influenza, a new study reports an ...
- Influenza is here. What can Albertans expect?
Influenza has arrived in Alberta and while its gaining traction later in the season than last year, some are concerned that with COVID-19 hospitalizations remaining high, hospitals could struggle ...
- Single-Component Multilayered Self-Assembling Protein Nanoparticles Displaying Extracellular Domains of Matrix Protein 2 as a Pan-influenza A Vaccine
The development of a cross-protective pan-influenza A vaccine remains a significant challenge. In this study, we designed and evaluated single-component self-assembling protein nanoparticles (SApNPs) ...
Go deeper with Google Headlines on:
Nanoparticle flu vaccine
[google_news title=”” keyword=”nanoparticle flu vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]